COSCIENS Biopharma Inc. (TSX:CSCI)
Canada · Delayed Price · Currency is CAD 2.690
-0.190 (-6.60%)
May 29, 2026, 3:59 PM EST
COSCIENS Biopharma Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 8 | 7.5 | 9.59 | 7.14 | 14.57 | 5.26 | |
Revenue Growth (YoY) | -10.29% | -21.79% | 34.22% | -50.98% | 177.03% | 44.03% |
Cost of Revenue | 5 | 4.93 | 4.86 | 4.21 | 6.02 | 0.09 |
Gross Profit | 3 | 2.57 | 4.73 | 2.94 | 8.56 | 5.17 |
Selling, General & Admin | 8.88 | 10.06 | 6.37 | 5.53 | 2.87 | 7.27 |
Research & Development | 2.63 | 2.95 | 8.3 | 2.04 | 1.37 | 6.57 |
Operating Expenses | 11.51 | 13.01 | 14.67 | 7.57 | 4.24 | 13.84 |
Operating Income | -8.51 | -10.44 | -9.94 | -4.63 | 4.32 | -8.67 |
Interest Expense | -0.15 | -0.17 | -0.13 | -0.14 | -0.14 | -0.01 |
Interest & Investment Income | 0.2 | 0.28 | 0.44 | 0.06 | 0.15 | - |
Currency Exchange Gain (Loss) | -0.16 | -0.2 | 0.05 | -0.02 | 0.21 | 0.22 |
Other Non Operating Income (Expenses) | 1 | 0.41 | 2.7 | 0.36 | -0.01 | -0.01 |
EBT Excluding Unusual Items | -7.62 | -10.11 | -6.89 | -4.37 | 4.53 | -8.48 |
Merger & Restructuring Charges | - | - | -4.08 | - | - | - |
Asset Writedown | -0.24 | -0.24 | -4.26 | - | - | - |
Pretax Income | -7.86 | -10.35 | -15.23 | -4.37 | 4.53 | -8.48 |
Income Tax Expense | 0.01 | 0.01 | 0.08 | -0.89 | 1.08 | -0.11 |
Earnings From Continuing Operations | -7.87 | -10.36 | -15.31 | -3.49 | 3.45 | -8.37 |
Earnings From Discontinued Operations | 11.92 | - | - | - | - | - |
Net Income | 4.05 | -10.36 | -15.31 | -3.49 | 3.45 | -8.37 |
Net Income to Common | 4.05 | -10.36 | -15.31 | -3.49 | 3.45 | -8.37 |
Shares Outstanding (Basic) | 3 | 3 | 3 | 2 | 2 | 1 |
Shares Outstanding (Diluted) | 3 | 3 | 3 | 2 | 2 | 1 |
Shares Change (YoY) | 8.91% | 22.62% | 39.74% | -0.39% | 61.37% | 179.74% |
EPS (Basic) | 1.28 | -3.27 | -5.93 | -1.89 | 1.87 | -7.28 |
EPS (Diluted) | 1.28 | -3.27 | -5.93 | -1.89 | 1.86 | -7.28 |
Free Cash Flow | -8.86 | -9.18 | -15.73 | -3.3 | 4.93 | -8.61 |
Free Cash Flow Per Share | -2.80 | -2.90 | -6.09 | -1.79 | 2.66 | -7.49 |
Gross Margin | 37.44% | 34.29% | 49.33% | 41.13% | 58.71% | 98.29% |
Operating Margin | -106.41% | -139.25% | -103.70% | -64.81% | 29.65% | -164.85% |
Profit Margin | 50.68% | -138.14% | -159.69% | -48.79% | 23.66% | -159.09% |
Free Cash Flow Margin | -110.80% | -122.42% | -164.07% | -46.26% | 33.80% | -163.71% |
EBITDA | -7.57 | -9.52 | -8.68 | -3.19 | 5.79 | -8.53 |
EBITDA Margin | -94.64% | -126.90% | -90.52% | -44.60% | 39.72% | -162.09% |
D&A For EBITDA | 0.94 | 0.93 | 1.26 | 1.44 | 1.47 | 0.15 |
EBIT | -8.51 | -10.44 | -9.94 | -4.63 | 4.32 | -8.67 |
EBIT Margin | -106.41% | -139.25% | -103.70% | -64.81% | 29.65% | -164.85% |
Effective Tax Rate | - | - | - | - | 23.85% | - |